What about incorporating selenium in the therapeutic regimen of
SARS-CoV-2?
- Bachir Benarba
, - Atanasio Pandiella
Atanasio Pandiella
Instituto de Biología Molecular y Celular del Cáncer, CSIC-IBSAL-Universidad de Salamanca, Campus Miguel de Unamuno, Salamanca, Spain
Author ProfileAbstract
We suggest that patients with COVID-19 may be at higher risk for
selenium deficiency and, therefore, their selenium status should be
assessed. Moreover, we suggest incorporating selenium supplementation to
enhance their immune response and reduce the SARS-CoV-2 virulence.
